Compare KNTK & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNTK | ACAD |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.8B |
| IPO Year | 2017 | 2000 |
| Metric | KNTK | ACAD |
|---|---|---|
| Price | $47.98 | $26.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 22 |
| Target Price | ★ $48.58 | $30.55 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.53% | N/A |
| EPS Growth | ★ 157.84 | 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | $160,617,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $7.80 | $18.80 |
| Revenue Next Year | $13.93 | $11.70 |
| P/E Ratio | ★ N/A | $1,320.00 |
| Revenue Growth | 8.23 | ★ 40.45 |
| 52 Week Low | $31.33 | $19.69 |
| 52 Week High | $51.51 | $28.35 |
| Indicator | KNTK | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 74.40 |
| Support Level | $44.64 | $25.40 |
| Resistance Level | $49.06 | $27.79 |
| Average True Range (ATR) | 1.41 | 0.94 |
| MACD | 0.08 | 0.23 |
| Stochastic Oscillator | 42.97 | 82.17 |
Kinetik Holdings Inc is a midstream operator that provides comprehensive gathering, transportation, compression, processing and treating services. Its activities also include NGL stabilization and transportation, produced water gathering and disposal, and crude oil gathering, stabilization, storage, and transportation. The company operates in two reportable segments: i) The Midstream Logistics segment operates under three service offerings: 1) gas gathering and processing, 2) crude oil gathering, stabilization, and storage services, and 3) produced water gathering and disposal. ii) The Pipeline Transportation segment consists of two EMI Pipelines originating in the Permian Basin with various access points to the U.S. Gulf Coast, Kinetik NGL Pipelines, and Delaware Link Pipeline.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.